Choosing a Korea License Holder: Subsidiary, Distributor or Independent KLH
Updated: 2026-11-11 · GRZAN Regulatory Team · Verification date 2026-10-20
1. Key takeaways
Licence holders in Korea can take three forms: a local subsidiary, a distributor holding the licence, or an independent third-party KLH. The three forms are identical in regulatory qualification, since each must satisfy the same 4 conditions of business premises, dedicated quality manager, valid import business licence and MFDS registration. The difference lies in commercial control: whoever holds the licence also holds the import channel, so the three arrangements differ sharply in who actually controls market access.
- The core conclusion is that the licence holder controls the right to import. A distributor holding the licence hands the decision on whether importation is possible to the channel party; once cooperation breaks down, the manufacturer loses both the licence holder and the import channel.
- Identical Product Registration (IPR) provides a splitting mechanism: the same product may be held for registration by one entity and actually imported by another. This mechanism does not apply to Class 1 notification.
- Exit cost, not regulatory qualification, is the real differentiator among the three arrangements, and it should drive the selection decision.
2. Legal basis
The eligibility conditions and the IPR mechanism rest on the following instruments, which can be traced through the regulation names, document numbers, publication dates and provisions listed below.
| Regulation (Korean) | Number | Publication date | Provision |
| Medical Devices Act / 의료기기법 | Act No. 6909 (enactment) | Enacted and promulgated on 29 May 2003, effective 30 May 2004 | Article 15 (licence for the import business) |
| Regulations on Approval, Certification and Notification of Medical Devices, etc. / 의료기기 허가·인증·신고 등에 관한 규정 | MFDS Public Notice No. 2022-52 | Effective 29 July 2022 | Provisions on applicant entities and identical product registration |
| Enforcement Rule of the Medical Devices Act / 의료기기법 시행규칙 | Prime Ministerial Decree No. 2127 | Partially amended and effective 1 July 2026 | Attached Table 1 (standards and procedures for classification and designation of medical devices) |
| Medical Devices Act (item renewal) / 의료기기법 | Act No. 17248 (2020 amendment) | Promulgated 7 April 2020, effective 8 October 2020 | Article 49 (item renewal every 5 years) |
| Standards for Manufacturing and Quality Management of Medical Devices (KGMP) / 의료기기 제조 및 품질관리 기준 | MFDS Public Notice No. 2023-79 | 2023 | Mandatory for Class 2 to 4; certificate valid for 3 years |
3. Expert insights
Insight 1: The three arrangements differ not in regulatory qualification but in exit cost. With a local subsidiary, licence holding and import are both controlled by the manufacturer itself, giving the lowest exit cost, but the subsidiary requires real investment in people, premises and a quality system, and set-up and maintenance costs are high (the specific amounts are a practical estimate and vary with the form of establishment and staffing). A distributor holding the licence is fastest and cheapest at the outset but carries the highest exit cost. An independent third-party KLH sits between the two: licence holding is separated from distribution, the manufacturer keeps the freedom to change channels, and no legal entity needs to be built. GRZAN’s decision sequence for clients is to assess channel stability first, then decide whether a subsidiary is worthwhile. Channel stability can be narrowed down with two questions: is it possible within the next 3 years that distributors will be changed or added, and does the current distributor accept a separation of licence holding from distribution. If either answer points to uncertainty, distributor-held licensing is not appropriate.
Insight 2: The commercial constraints of distributor-held licensing are structural and cannot be solved by contract terms. Even where the contract requires the distributor to cooperate in changing the licence holder, the change still requires statutory procedures and a re-arrangement of the import channel, with a supply interruption window in between. This constraint originates in the structure of holding the licence equals being able to import; it is a result of institutional design, not a breach by either party. GRZAN recommends ruling out the distributor-held option when the channel is not yet stable or when multiple brands and multiple distributors are planned in parallel.
Insight 3: The splitting value of Identical Product Registration is widely underestimated. IPR allows the licence-holding and import roles for the same product to be carried by different entities, which makes the combination of licence with the KLH and import with the distributor workable in practice. Its boundary has 2 limits: first, IPR does not apply to Class 1 notification; second, the division of post-market obligations among the parties after the split must still be defined in writing, otherwise incident reporting coordination and MFDS liaison will run into a responsibility vacuum. GRZAN typically adopts this structure directly in projects with multi-distributor layouts.
Insight 4: Intellectual property and data ownership are hidden variables in the selection decision. The licence holder controls the registration dossier, the Korean-language technical documents and the correspondence records with MFDS. If these assets sit with the distributor, the manufacturer loses both the documents and the data when changing channels. GRZAN recommends listing ownership of technical documents and registration dossiers, and the obligation to deliver copies, as separate clauses in the licence holder agreement, rather than leaving them to default assumptions that follow the licence holder.
4. Practical recommendations
- Select on channel stability rather than on cost alone. Where the channel is stable and exclusive over the long term, distributor-held licensing is acceptable; where the channel is undecided or multiple distributors run in parallel, use an independent third-party KLH instead.
- Clarify the applicability boundaries of IPR. Where a split of licence holding and importation via IPR is planned, first confirm the device class, because Class 1 notification does not qualify for IPR.
- Write document and data ownership into the agreement. Ownership of technical documents, Korean-language materials and MFDS correspondence, together with the obligation to deliver copies, must be agreed separately.
- Preset the licence holder change procedure in the agreement, including trigger conditions, notice periods and import arrangements during the change, to avoid supply interruption when a change occurs.
- Assess the continuity of the licence holder arrangement on a 5-year cycle. Item renewal occurs every 5 years, and short-term channel arrangements cannot support a full cycle.
5. Verification checklist
- □ Candidate licence holder type: distinguish subsidiary, distributor and independent third-party KLH; the type is clear and its pros and cons have been assessed in writing.
- □ The 4 eligibility conditions: verify business premises, dedicated quality manager, import business licence and MFDS registration; all 4 are satisfied.
- □ Separation of licence holding and distribution: check whether the licence holder and the distributor are the same entity; a clear choice has been made in line with the channel strategy.
- □ IPR applicability: verify the device class; IPR may be used only where the route is not Class 1 notification.
- □ Import channel arrangement: check the importing entity under an IPR split; the licence-holding and import roles are divided in writing.
- □ Document and data ownership: review the ownership and copy-delivery clauses of the agreement; ownership of technical documents and registration dossiers is clearly defined.
- □ Change and exit arrangements: review the change procedure clauses of the agreement; they include trigger conditions, deadlines and transition arrangements.
- □ Regulatory information verified as of 29 October 2026 (pending verification for any later amendments).
How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, Korean licence holder and local testing support for the Republic of Korea. Our team coordinates licence holder arrangements, import business registration, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com
Disclaimer
Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.
About GRZAN
GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.
GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.
Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.
What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.
Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.
Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.
Take your devices global with GRZAN
We work with manufacturers worldwide to open new markets with a clear regulatory pathway.
Contact us